Alexander B. Stillebroer

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Experience of 5 years adjustable continence therapy (ProACT): the surgical learning curve and patient outcomes.

Experience of 5 years adjustable continence therapy (ProACT): the surgical learning curve and patient outcomes.

Journal: World journal of urology
Published: June 04, 2025

Addressing bladder and bowel challenges in dutch multiple sclerosis patients: Symptom prevalence and patient referral pathways.

Addressing bladder and bowel challenges in dutch multiple sclerosis patients: Symptom prevalence and patient referral pathways.

Journal: PloS one
Published: March 26, 2024

Two-Staged Sacral Neuromodulation for the Treatment of Nonobstructive Urinary Retention: A Multicenter Study Assessing Predictors of Success.

Two-Staged Sacral Neuromodulation for the Treatment of Nonobstructive Urinary Retention: A Multicenter Study Assessing Predictors of Success.

Journal: Neuromodulation : journal of the International Neuromodulation Society
Published: November 09, 2021

A chancre instead of cancer

A chancre instead of cancer

Journal: Nederlands tijdschrift voor geneeskunde
Published: July 31, 2019

Management of ureteropelvic junction obstruction in children-a roundtable discussion.

Management of ureteropelvic junction obstruction in children-a roundtable discussion.

Journal: Journal of pediatric urology
Published: March 20, 2019

Correspondence: Training opportunities in renal replacement access.

Correspondence: Training opportunities in renal replacement access.

Journal: Journal of pediatric urology
Published: September 24, 2017

Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.

Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.

Journal: European urology
Published: June 10, 2015

Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.

Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 13, 2014

Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.

Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 08, 2014

ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.

ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.

Journal: Cancer biotherapy & radiopharmaceuticals
Published: May 24, 2013

Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

Journal: European urology
Published: May 31, 2012

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 14, 2011
Showing 1-12 of 12

Last Updated: 09/26/2026